Erratum: Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy (Science DOI: 10.1126/science.aar3593);Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy

Science

Volumn 362, Issue 6411, 2018, Pages

  Cristescu, Razvan ^a   Mogg, Robin ^a,f   Ayers, Mark ^a   Albright, Andrew ^a   Murphy, Erin ^a   Yearley, Jennifer ^a   Sher, Xinwei ^a   Liu, Xiao Qiao ^a   Lu, Hongchao ^a   Nebozhyn, Michael ^a   Zhang, Chunsheng ^a   Lunceford, Jared K ^a   Joe, Andrew ^a   Cheng, Jonathan ^a   Webber, Andrea L ^a   Ibrahim, Nageatte ^a   Plimack, Elizabeth R ^b   Ott, Patrick A ^c   Seiwert, Tanguy Y ^d   Ribas, Antoni ^e   McClanahan, Terrill K ^a   Tomassini, Joanne E ^a   Loboda, Andrey ^a   Kaufman, David ^a,f   more..

^a MERCK RESEARCH LABORATORIES   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Bill and Melinda Gates Medical Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MRNA EDITING ENZYME CATALYTIC POLYPEPTIDE LIKE; DNA; DNA DIRECTED DNA POLYMERASE EPSILON; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; RNA; VALINE; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; TRANSCRIPTOME; TUMOR MARKER;

ANTIBODY; BIOLOGY; BIOMARKER; CANCER; CANCRINITE; CELL COMPONENT; GENE; GENE EXPRESSION; STRATIFICATION; TUMOR;

ADVANCED CANCER; ANTIGENICITY; ARTICLE; CANCER GENETICS; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL FEATURE; COPY NUMBER VARIATION; CORRELATION ANALYSIS; CYTOTOXIC T LYMPHOCYTE; DATA BASE; DIGESTIVE SYSTEM CANCER; ENDOMETRIUM CARCINOMA; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC MARKER; GERMLINE MUTATION; GLIOBLASTOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MELANOMA; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MUTAGENESIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; SMALL CELL LUNG CANCER; SMOKING; SOMATIC MUTATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR MUTATIONAL BURDEN; TUMOR VOLUME; UROGENITAL TRACT TUMOR; WHOLE GENOME SEQUENCING; YOUDEN INDEX; ANTAGONISTS AND INHIBITORS; CELL CYCLE CHECKPOINT; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; INFLAMMATION; MOLECULARLY TARGETED THERAPY; MUTATION; NEOPLASM; PROCEDURES;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; BIOMARKERS, TUMOR; CELL CYCLE CHECKPOINTS; GENETIC MARKERS; HUMANS; IMMUNOTHERAPY; INFLAMMATION; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES; TRANSCRIPTOME; TUMOR BURDEN;

EID: 85054777584     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.aax1384     Document Type: Erratum

References (59)

1. S. J. Lee et al., Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett. 580, 755-762 (2006). Doi: 10.1016/j.febslet.2005.12.093; pmid: 16413538
2. C. Lu, P. S. Redd, J. R. Lee, N. Savage, K. Liu, The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells. Oncoimmunology 5, e1247135 (2016). Doi: 10.1080/2162402X.2016.1247135; pmid: 28123883
3. J. M. Taube et al., Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 20, 5064-5074 (2014). Doi: 10.1158/1078-0432.CCR-13-3271; pmid: 24714771
4. A. Snyder et al., Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189-2199 (2014). Doi: 10.1056/NEJMoa1406498; pmid: 25409260
5. E. M. Van Allen et al., Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207-211 (2015). Doi: 10.1126/science.aad0095; pmid: 26359337
6. W. Hugo et al., Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35-44 (2016). Doi: 10.1016/j.cell.2016.02.065; pmid: 26997480
7. D. B. Johnson, M. H. Pollack, J. A. Sosman, Emerging targeted therapies for melanoma. Expert Opin. Emerg. Drugs 21, 195-207 (2016). Doi: 10.1080/14728214.2016.1184644; pmid: 27148822
8. N. A. Rizvi et al., Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124-128 (2015). Doi: 10.1126/science.aaa1348; pmid: 25765070
9. M. Kowanetz et al., Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC. Ann. Oncol. 27, 77P (2016). Doi: 10.1093/annonc/mdw363.25
10. D. T. Le et al., Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409-413 (2017). Doi: 10.1126/science.aan6733; pmid: 28596308
11. D. T. Le et al., PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509-2520 (2015). Doi: 10.1056/NEJMoa1500596; pmid: 26028255
12. J. E. Rosenberg et al., Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet 387, 1909-1920 (2016). Doi: 10.1016/S0140-6736(16)00561-4; pmid: 26952546
13. M. S. Rooney, S. A. Shukla, C. J. Wu, G. Getz, N. Hacohen, Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48-61 (2015). Doi: 10.1016/j.cell.2014.12.033; pmid: 25594174
14. P. C. Tumeh et al., PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568-571 (2014). Doi: 10.1038/nature13954; pmid: 25428505
15. M. Ayers et al., IFN-g-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930-2940 (2017). Doi: 10.1172/JCI91190; pmid: 28650338
16. The Cancer Genome Atlas, TCGA Data Portal; https://tcga-data.nci.nih.gov/docs/publications/tcga/.
17. L. B. Alexandrov, M. R. Stratton, Mutational signatures: The patterns of somatic mutations hidden in cancer genomes. Curr. Opin. Genet. Dev. 24, 52-60 (2014). Doi: 10.1016/j.gde.2013.11.014; pmid: 24657537
18. R. Haddad et al., Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma. J. Clin. Oncol. 35 (Suppl.), 6009 (2017). Doi: 10.1200/JCO.2017.35.15-suppl.6009
19. D. B. Johnson et al., Targeted next generation sequencing identifies markers of response to PD-1 blockade. Cancer Immunol. Res. 4, 959-967 (2016). Doi: 10.1158/2326-6066. CIR-16-0143; pmid: 27671167
20. A. Panda et al., Identifying a clinically applicable mutational burden threshold as a potential biomarker of response to immune checkpoint therapy in solid tumors. JCO Precis. Oncol. 2017, 10.1200/PO.17.00146 (2017). Pmid: 29951597
21. T. Y. Seiwert et al., "Biomarkers predictive of response to pembrolizumab in head and neck cancer (HNSCC), " in Proceedings of the American Association for Cancer Research Annual Meeting 2018, Chicago, IL, 14 to 18 April 2018 (American Association for Cancer Research, 2018), abstract no. LB-339.
22. S. J. Salipante, S. M. Scroggins, H. L. Hampel, E. H. Turner, C. C. Pritchard, Microsatellite instability detection by next generation sequencing. Clin. Chem. 60, 1192-1199 (2014). Doi: 10.1373/clinchem.2014.223677; pmid: 24987110
23. W. Roh et al., Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci. Transl. Med. 9, eaah3560 (2017). Doi: 10.1126/scitranslmed.aah3560; pmid: 28251903
24. N. McGranahan et al., Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463-1469 (2016). Doi: 10.1126/science.aaf1490; pmid: 26940869
25. E. B. Garon et al., Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018-2028 (2015). Doi: 10.1056/NEJMoa1501824; pmid: 25891174
26. C. Robert et al., Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521-2532 (2015). Doi: 10.1056/NEJMoa1503093; pmid: 25891173
27. M. R. Neagu, D. A. Reardon, An update on the role of immunotherapy and vaccine strategies for primary brain tumors. Curr. Treat. Options Oncol. 16, 54 (2015). Doi: 10.1007/s11864-015-0371-3; pmid: 26454859
28. U. Vaishampayan, Therapeutic options and multifaceted treatment paradigms in metastatic castrate-resistant prostate cancer. Curr. Opin. Oncol. 26, 265-273 (2014). Doi: 10.1097/CCO.0000000000000066; pmid: 24626129
29. D. Coppola et al., Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am. J. Pathol. 179, 37-45 (2011). Doi: 10.1016/j.ajpath.2011.03.007; pmid: 21703392
30. J. Galon, H. K. Angell, D. Bedognetti, F. M. Marincola, The continuum of cancer immunosurveillance: Prognostic, predictive, and mechanistic signatures. Immunity 39, 11-26 (2013). Doi: 10.1016/j.immuni.2013.07.008; pmid: 23890060
31. M. Luksza et al., A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. Nature 551, 517-520 (2017). Pmid: 29132144
32. H. Dai et al., A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res. 65, 4059-4066 (2005). Doi: 10.1158/0008-5472.CAN-04-3953; pmid: 15899795
33. S. Spranger, R. Bao, T. F. Gajewski, Melanoma-intrinsic b-catenin signalling prevents anti-tumour immunity. Nature 523, 231-235 (2015). Doi: 10.1038/nature14404; pmid: 25970248
34. K. Yoshihara et al., Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 4, 2612 (2013). Doi: 10.1038/ncomms3612; pmid: 24113773
35. A. C. Huang et al., T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545, 60-65 (2017). Doi: 10.1038/nature22079; pmid: 28397821
36. P. F. Robbins et al., Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumorreactive T cells. Nat. Med. 19, 747-752 (2013). Doi: 10.1038/nm.3161; pmid: 23644516
37. N. H. Segal et al., Epitope landscape in breast and colorectal cancer. Cancer Res. 68, 889-892 (2008). Doi: 10.1158/0008-5472.CAN-07-3095; pmid: 18245491
38. H. Matsushita et al., Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482, 400-404 (2012). Doi: 10.1038/nature10755; pmid: 22318521
39. M. Dolled-Filhart et al., Development of a companion diagnostic for pembrolizumab in non-small cell lung cancer using immunohistochemistry for programmed death ligand-1. Arch. Pathol. Lab. Med. 140, 1243-1249 (2016). Doi: 10.5858/arpa.2015-0542-OA; pmid: 27552095
40. L. Q. Chow et al., A phase Ib study of pembrolizumab (pembro; MK-3475) in patients (pts) with human papillomavirus virus (HPV)-positive and negative head and neck cancer (HNC). Ann. Oncol. 25 (Suppl. 4), 14 (2014). Doi: 10.1093/annonc/mdu438.32
41. T. Y. Seiwert et al., Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial. Lancet Oncol. 17, 956-965 (2016). Doi: 10.1016/S1470-2045(16)30066-3; pmid: 27247226
42. O. Hamid et al., Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134-144 (2013). Doi: 10.1056/NEJMoa1305133; pmid: 23724846
43. H. Li, R. Durbin, Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760 (2009). Doi: 10.1093/bioinformatics/btp324; pmid: 19451168
44. A. McKenna et al., The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297-1303 (2010). Doi: 10.1101/gr.107524.110; pmid: 20644199
45. K. Cibulskis et al., Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213-219 (2013). Doi: 10.1038/nbt.2514; pmid: 23396013
46. S. T. Sherry, M. Ward, K. Sirotkin, dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation. Genome Res. 9, 677-679 (1999). Pmid: 10447503
47. S. A. Forbes et al., COSMIC (the Catalogue of Somatic Mutations in Cancer): A resource to investigate acquired mutations in human cancer. Nucleic Acids Res. 38, D652-D657 (2010). Doi: 10.1093/nar/gkp995; pmid: 19906727
48. A. Szolek et al., OptiType: Precision HLA typing from nextgeneration sequencing data. Bioinformatics 30, 3310-3316 (2014). Doi: 10.1093/bioinformatics/btu548; pmid: 25143287
49. M. Nielsen et al., Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci. 12, 1007-1017 (2003). Doi: 10.1110/ps.0239403; pmid: 12717023
50. O. Lund et al., Definition of supertypes for HLA molecules using clustering of specificity matrices. Immunogenetics 55, 797-810 (2004). Doi: 10.1007/s00251-004-0647-4; pmid: 14963618
51. J. Sidney, B. Peters, N. Frahm, C. Brander, A. Sette, HLA class I supertypes: A revised and updated classification. BMC Immunol. 9, 1 (2008). Doi: 10.1186/1471-2172-9-1; pmid: 18211710
52. W. McLaren et al., The Ensembl Variant Effect Predictor. Genome Biol. 17, 122 (2016). Doi: 10.1186/s13059-016-0974-4; pmid: 27268795
53. R. Rosenthal, N. McGranahan, J. Herrero, B. S. Taylor, C. Swanton, DeconstructSigs: Delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol. 17, 31 (2016). Doi: 10.1186/s13059-016-0893-4; pmid: 26899170
54. L. B. Alexandrov et al., Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013). Doi: 10.1038/nature12477; pmid: 23945592
55. D. C. Koboldt et al., VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568-576 (2012). Doi: 10.1101/gr.129684.111; pmid: 22300766
56. F. Favero et al., Sequenza: Allele-specific copy number and mutation profiles from tumor sequencing data. Ann. Oncol. 26, 64-70 (2015). Doi: 10.1093/annonc/mdu479; pmid: 25319062
57. A. Roth et al., PyClone: Statistical inference of clonal population structure in cancer. Nat. Methods 11, 396-398 (2014). Doi: 10.1038/nmeth.2883; pmid: 24633410
58. M. Dolled-Filhart et al., Development of a prototype immunohistochemistry assay to measure programmed death ligand-1 expression in tumor tissue. Arch. Pathol. Lab. Med. 140, 1259-1266 (2016). Doi: 10.5858/arpa.2015-0544-OA; pmid: 27788043
59. A. I. Daud et al., Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J. Clin. Oncol. 34, 4102-4109 (2016). Doi: 10.1200/JCO.2016.67.2477; pmid: 27863197